(Q48311790)

10 February 2018

title

Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. (English)

1 reference

10 February 2018

chronic renal insufficiency

main subject

1 reference

Alberto Ortiz

2

0 references

author name string

BinBin Zheng-Lin

series ordinal

1

1 reference

10 February 2018

publication date

3 January 2018

1 reference

10 February 2018

published in

Drugs

1 reference

10 February 2018

volume

78

1 reference

10 February 2018

issue

2

1 reference

10 February 2018

page(s)

215-229

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s40265-017-0858-2

exact match

0 references

cites work

Cardiovascular disease in Europe 2014: epidemiological update

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Looking into the crystal ball-upcoming drugs for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Chronic kidney disease as a coronary artery disease risk equivalent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Genetic and metabolic determinants of plasma PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

PCSK9 in diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Niacin: the evidence, clinical use, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0858-2

Explained and unexplained ischemic heart disease risk after renal transplantation

21 January 2018

1 reference

12 December 2020

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

12 December 2020

Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction

1 reference

12 December 2020

Cardiovascular disease in patients with renal disease: the role of statins

1 reference

12 December 2020

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

1 reference

12 December 2020

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

12 December 2020

Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).

1 reference

12 December 2020

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

12 December 2020

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

1 reference

12 December 2020

1 reference

12 December 2020

Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment

1 reference

12 December 2020

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation

1 reference

12 December 2020

Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.

1 reference

12 December 2020

Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline

1 reference

12 December 2020

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

1 reference

12 December 2020

Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering

1 reference

12 December 2020

Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy

1 reference

12 December 2020

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

1 reference

12 December 2020

Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement

1 reference

12 December 2020

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

12 December 2020

Evolocumab (AMG 145) for primary hypercholesterolemia

1 reference

12 December 2020

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

1 reference

12 December 2020

Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention

1 reference

12 December 2020

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.

1 reference

12 December 2020

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

1 reference

12 December 2020

Serum lipoprotein(a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines

1 reference

12 December 2020

Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences

1 reference

12 December 2020

Pharmacokinetics interactions of monoclonal antibodies.

1 reference

12 December 2020

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

1 reference

12 December 2020

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

1 reference

12 December 2020

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

1 reference

12 December 2020

Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody

1 reference

12 December 2020

Lipoprotein(a) in nephrological patients

1 reference

12 December 2020

PCSK9 inhibitors: A new era of lipid lowering therapy.

1 reference

12 December 2020

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

12 December 2020

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

1 reference

12 December 2020

Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.

1 reference

12 December 2020

High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients.

1 reference

12 December 2020

Prevalence of chronic kidney disease and association with cardiovascular risk factors among teachers in Cape Town, South Africa

1 reference

12 December 2020

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

1 reference

12 December 2020

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).

1 reference

12 December 2020

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

1 reference

12 December 2020

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

1 reference

12 December 2020

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

1 reference

12 December 2020

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment

1 reference

12 December 2020

10.1007/S40265-017-0858-2

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

29299849

1 reference

10 February 2018